Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Video FDA approves 1st mRNA flu shot

26 September 2026 · By · Wire by Fusion42

Published

26 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at abcnews.com →

◆ Verified

Fusion42 · 27 September 2026 · Fusion42 review

The FDA has approved the first mRNA-based influenza vaccine, which promises improved protection against the flu compared to traditional vaccines.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it between 19 Sep 2026 and 26 Sep 2026.

◆ ◆ The Wire takeaway

The US market for flu vaccines opens to mRNA technology providers with FDA approval now secured. You can pivot or expand your vaccine portfolio to include novel mRNA flu shots and gain access to healthcare channels prioritising this innovation.

◆ Coverage

3 sources · first reported 19 Sep 2026 · latest 26 Sep 2026

◆ Related on Wire

◆ Topics

Biotechfda-approvalmRNAflu-vaccinepublic-healthbiotech